5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

January 10, 2024 updated by: Lawson Health Research Institute
In December 2015, Health Canada issued a warning about a potential relationship between suicide and finasteride use and called for further research. No population based studies have assessed the risk of suicide with finasteride use, and this risk is not currently part of the product monograph. Furthermore, the link between depression and finasteride has not been well studied in the older population who are the primary users of this medication.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

186394

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

64 years and older (Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All men >66 years of age in Ontario between 2003-2013

Description

Inclusion Criteria:

  • All men >66 years of age in Ontario between 2003-2013

Exclusion Criteria:

  • Non Ontario residents
  • No prescriptions filled in prior 180 days
  • Prior exposure to finasteride/dutasteride in the 2 years prior to study enrollment.
  • Prescription initiated during hospital admission or ER visit.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
5ARI Users
Exposure to finasteride/dutasteride
Non 5ARI users

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Suicide (Based on Administrative Data Elements From Ontario Registrar General Death Database, National Ambulatory Care Reporting System, Hospital Discharge Abstracts, and Ontario Regional Mental Health Database)
Time Frame: Through study completition, an average of 18 months.
  1. Ontario Registrar General Death database. Use the COD_primary variable (used from 2003 onwards) to define suicide, based on an ICD10 code of X60-X84.
  2. NACRS: X60-84 (dx10code1-dx10code10) AND dead on arrival or death after arrival (visdisp2002 = 10 or 11). Consider admission date the date of the event.
  3. OMHRS: Discharge reason (dischreason (X90) = 2). Died from suicide. Consider admission date the date of the event.
  4. CIHI-DAD (Consider admission date the date of the event):

i. suicide=1, or ii. dx10code1-25= ICD10 X60-84 AND dischdisp="07".

Through study completition, an average of 18 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Suicide Attempt (Based on Administrative Data Elements From National Ambulatory Care Reporting System, and Ontario Regional Mental Health Database)
Time Frame: Through study completition, an average of 18 months.
  1. NACRS: presentation to the emergency room: ICD 10 codes X60-X84 (intentional self harm).
  2. OMHRS: admission with suicide ideation.

i. Self injury attempts: D1A or selfinjury_attempt=3, 4, 5, or 6 ii. Self injury intent: D1B or selfinjury_intent=1 iii. Self injury considered: D1C or selfinjury_cons=3, 4, 5 or 6 iv. Self injury plan: D1DB or suicide_plan=1

Through study completition, an average of 18 months.
Depression (Based on Administrative Data Elements From Hospital Discharge Abstract Database, and Ontario Regional Mental Health Database and Ontario Health Insurance Plan)
Time Frame: Through study completition, an average of 18 months.
  1. Any CIHI-DAD/SDS ICD 10 code, OR
  2. Any OMRHS code Axis1_dsm4code1-19 or Axis2_dsm4code 1-7 OR
  3. Look for any OHIP record billed by Mainspecialty = "PSYCHIATRY" with a diagnosis of depression OHIP dxcode 311, OR
  4. ≥2 GP visits within 2 years AND both with OHIP dxcode 311

i. OHIP dxcode: 311 ii. ICD 10: F32.0, F32.1, F32.2, F32.3, F32.8, F32.9, F33.0, F33.1, F33.2, F33.3, F33.4, F33.8, F34.1 iii. Psychiatry visits defined as any of these OHIP fee codes: A195, A895, A190, A795, A695, A395, A196, A193, A194, A191, A192 iv. OMHRS: 29620-29626, 29630-29636, 31100 (major depressive disorder)

Through study completition, an average of 18 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2003

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

August 5, 2016

First Submitted That Met QC Criteria

August 18, 2016

First Posted (Estimated)

August 24, 2016

Study Record Updates

Last Update Posted (Actual)

January 12, 2024

Last Update Submitted That Met QC Criteria

January 10, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2016 0906 192 000

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on 5ARI

3
Subscribe